Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05402371 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis
A Phase 2 study of NAFLD and Fibrosis, Liver, sponsored by Hepion Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 20
- Study locations
NCT05402371 is a Phase 2 study of NAFLD and Fibrosis, Liver that is active but no longer recruiting, run by Hepion Pharmaceuticals. The registered enrollment target is 120 participants, below the 161-participant average among 26 other NAFLD trials with a reported enrollment target (25% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT05402371, a Phase 2 study of NAFLD and Fibrosis, Liver, is active but no longer recruiting, sponsored by Hepion Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, double-blind, placebo-controlled, parallel-dosing, multi-center study to evaluate the efficacy and safety of Rencofilstat as evidenced by histopathological improvements in fibrosis in adult NASH subjects with F2 or F3 fibrosis (NASH CRN system). Antifibrotic biomarker activity will be evaluated on an exploratory basis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rencofilstat
Study Locations (20)
Florida
- Synergy Healthcare, LLC - Bradenton
- Tampa Bay Medical Research, Inc. - Clearwater
- Top Medical Research, Inc. - Cutler Bay
- Integrity Clinical Research, LLC - Doral
- Evolution Clinical Trials, Inc. - Hialeah Gardens
- Borland Groover Clinical Research - Jacksonville
- Ocala GI Research - Lady Lake
- Accel Research Sites-Lakeland CRU - Lakeland
- Future Care Solutions, LLC - Miami
Arizona
- Arizona Liver Health-Chandler - Chandler
- Arizona Liver Health - Peoria
- Adobe Clinical Research, LLC - Tucson
- Arizona Liver Health-Tuscon - Tucson
California
- National Research Institute - Huntington Park
- National Research Institute - Los Angeles
- National Research Institute - Panorama City
- National Research Institute - Santa Ana
Arkansas
- Preferred Research Partners, Inc. - Little Rock
- Arkansas Gastroenterology - North Little Rock
Alabama
- Medical Affiliated Research Center - Huntsville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2022-10-15 |
| Est. Completion | 2025-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05402371
The ClinicalTrials.gov registry entry for NCT05402371 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 161-participant average among 26 other NAFLD trials with a reported enrollment target (25% lower). The listed sponsor is Hepion Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with NAFLD appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05402371 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT05402371 about?
NCT05402371 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis". This is a randomized, double-blind, placebo-controlled, parallel-dosing, multi-center study to evaluate the efficacy and safety of Rencofilstat as evidenced by histopathological improvements in fibrosis in adult NASH subjects with F2 or F3 fibrosis (NASH CRN system). Antifibrotic biomarker activity ...
What is the current status of trial NCT05402371?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2022-10-15. Estimated completion is 2025-09.
What conditions does trial NCT05402371 study?
This clinical trial studies the following conditions: NAFLD, Fibrosis, Liver, Nonalcoholic Steatohepatitis (NASH).
What interventions are being tested in trial NCT05402371?
The interventions under investigation include: Placebo (DRUG), Rencofilstat (DRUG).
Who is sponsoring clinical trial NCT05402371?
This trial is sponsored by Hepion Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05402371 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NAFLD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant
RECRUITING · Phase 2
-
Digoxin In NASH (CODIN)
RECRUITING · Phase 2
-
A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH
ACTIVE NOT RECRUITING · Phase 2
-
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
ACTIVE NOT RECRUITING · Phase 2
-
Treating PCOS With Semaglutide vs Active Lifestyle Intervention
COMPLETED · Phase 2
-
Pathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.